ZernikeMeta et al. invest €2m in CellPly

ZMV invested via its €14m Ingenium Emilia Romagna II Fund. Atlante Seed is a €10m Intesa Sanpaolo Group fund managed by IMI Fondi Chiusi.

The seed funding provided will allow CellPly to further develop its diagnostics platform, which is being developed with the aim of discovering cellular responses to anti-tumour drugs in-vitro, rather than directly in a patient.

According to the company, the global in-vitro diagnostics market was worth around $50bn in 2012.

Company
Founded in 2013 and headquartered in Bologna, CellPly is developing diagnostic tools designed to gauge cellular responses to drug-based treatments towards the treatment of cancer. Its diagnostic platform is meant to measure the efficacy of immunotherapies and chemotherapies on cancer cells.

People
Massimo Bocchi is the CEO of CellPly. Andrea Ballestri is an investment director at Atlante Seed, while Antonio Leone is a partner and director at IAG.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Southern Europe
• Early-stage
• Healthcare
• Italy